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Abstract
Calumenin isoforms 1 and 2 (calu-1/2), encoded by the CALU gene, belong to the CREC protein family. Calu-1/2 proteins are
secreted into the extracellular space, but the secretory process and regulatory mechanism are largely unknown. Here, using
a time-lapse imaging system, we visualized the intracellular transport and secretory process of calu-1/2-EGFP after their
translocation into the ER lumen. Interestingly, we observed that an abundance of calu-1/2-EGFP accumulated in cellular
processes before being released into the extracellular space, while only part of calu-1/2-EGFP proteins were secreted directly
after attaching to the cell periphery. Moreover, we found the secretion of calu-1/2-EGFP required microtubule integrity, and
that calu-1/2-EGFP-containing vesicles were transported by the motor proteins Kif5b and cytoplasmic dynein. Finally, we
determined the export signal of calu-1/2-EGFP (amino acid positions 20–46) and provided evidence that the asparagine at
site 131 was indispensable for calu-1/2-EGFP stabilization. Taken together, we provide a detailed picture of the intracellular
transport of calu-1/2-EGFP, which facilitates our understanding of the secretory mechanism of calu-1/2.
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Introduction
Human calumenin (calu), a CREC protein family member, is
encoded by the CALU gene (NCBI GeneID: 813) [1,2], which is
mapped on chromosome 7q32 [3]. Two alternative spliced
variants of the CALU gene are identified as calu-1 and calu-2
(also known as crocalbin) [4]. The two isoforms have equal lengths
(315 amino acids), with exons 3 and 4 exchanged [5], and are
ubiquitously expressed in human tissues [6]. Both calu-1 and -2
contain an N-terminal signal sequence (19 amino acids) and seven
EF-hand domains for binding Ca
2+ [7]. Previous reports show that
they localize to the secretory pathway and are secreted into the
extracellular space [8–10], while some researches insist that calu-
1/2 contained an ER-retaining signal HDEF at the C-terminus,
and are retained in the ER lumen [11–13]. Besides, proline at the
+2 position from the predicted signal peptide cleavage site of calu-
1/2 [6] acts as an export signal to mediate calu-1/2 secretion [14].
Extracellularly, calu-1 is reported to interact with the serum
amyloid P component in the presence of Ca
2+, indicating its
possible role in amyloidosis [15]. Calu-1 may also be involved in
autocrine and paracrine signaling since it decreases the expression
level of septin 2 and actin fragments as well as regulating the cell
cycle in fibroblasts [16]. Recently, thrombospondin-1, a secreted
glycoprotein, is reported to form a complex with calu-1, suggesting
that calu-1/2 play a potential role in hemostasis and thrombosis
[2].
Despite the initial characterization of calu-1/2, many aspects
are still elusive, including their intracellular transport and
secretory process. Here, we used calu-1/2-EGFP, in which the
EGFP would possibly mask the C-terminal HDEF retention signal,
to study its secretion process. We reported the translocation of
calu-1/2-EGFP into the lumen of the endoplasmic reticulum (ER),
visualized their intracellular transport in the vesicles, and showed
the secretion of calu-1/2-EGFP through either ‘‘secretion after
attachment’’ or ‘‘secretion after accumulation’’. To investigate the
underlying transport mechanism, we determined the roles of
cytoskeleton network and motor proteins on the intracellular
transport and secretion of calu-1/2-EGFP. Furthermore, we
identified that Kif5b and cytoplasmic dynein were the motors
that were responsible for their microtubule-dependent trafficking.
Finally, mutational analysis revealed the export signal of calu-1/2-
EGFP and amino acid point crucial for the calu-1/2-EGFP
stability.
Results
Calu-1/2 are translocated into the ER lumen and secreted
With our produced antibody, which recognize both calu-1 and
calu-2 isoforms (data not shown), we found that a great deal of
calu-1/2 were detected in the cultured medium (Figure 1A).
However, immunofluorescence assay showed that calu-1/2
localized throughout the cell in an ER-like manner rather than
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35344accumulated at the Golgi apparatus both in HeLa and HEK293T
cells (Figure S1). In order to specifically study the secretory process
of calu-1/2, we used calu-1/2-EGFP, in which the C-terminal ER-
retaining signal HDEF was disrupted by the EGFP tag. A majority
of calu-1/2-EGFP fusion proteins were detected in the cultured
medium as expected (Figure 1B). Meanwhile, calu-1/2-EGFP
accumulated at the Golgi apparatus both in HeLa and HEK293T
cells (Figure 1C and 1D), suggesting that the ER-retaining
pathway was blocked.
We then used digitonin, which selectively permeabilizes the
plasma membrane but not the intracellular membranes [17], to
treat the cells after fixation. Under this treatment, GM130, which
peripherally attaches to the cytoplasmic surface of the Golgi
apparatus, was detected by its antibody, whereas the ER luminal
protein PDI could not be recognized by its own antibody
(Figure S2). Similarly, the cytosolic EGFP tag of APP-EGFP
fusion protein was immunolabeled by anti-EGFP antibody,
whereas b4GalT-1-EGFP, whose EGFP is on the luminal side of
the ER and the Golgi apparatus, was not immunolabeled
(Figure 1E). Also, anti-EGFP antibody did not label the
overexpressed calu-1/2-EGFP by immunofluorescence after
digitonin treatment (Figure 1E), suggesting that calu-1/2 localized
in the lumen of the ER and the Golgi apparatus. Furthermore, to
determine the signal responsible for the entry of calu-1/2 into the
lumen, we generated several constructs of calu-2 and visualized
their subcellular localization, and found that the 19 amino acids on
the N-terminal were necessary and sufficient for the Golgi
localization of calu-2-EGFP (Figure 1F). These results, together
with the previous report that the N-terminal 19 amino acids of
calu-1 are cleaved [14], suggest that calu-1/2-EGFP are secreted
to the extracellular space, and that the N-terminal 19 amino acids
act as a signal peptide, which docks calu-1/2-EGFP to the ER and
then translocates them into the lumen of the endomembrane
system.
Figure 1. Calu-1/2 are translocated into the lumen and secreted. (A) Western blotting analysis of endogenous calu-1/2 from total cell lysate
(TCL) and cultured medium (CM) of HeLa cells. (B) Western blotting analysis of overexpressed calu-1/2-EGFP of HeLa cells. Samples of TCL and CM
were separated by SDS-PAGE and probed with anti-EGFP and anti-tubulin antibodies. Coomassie Blue staining (Co.St.) was used as a loading control
of CM. (C) Immunofluorescence of EGFP or Calu-1/2-EGFP overexpressing HeLa cells probed with anti-Giantin antibody. Bar, 10 mm. (D)
Immunofluorescence of EGFP or Calu-2-EGFP overexpressing HEK293T cells probed with anti-Giantin antibody. Bar, 10 mm. (E) HeLa cells were
immunofluorescently labeled by the indicated antibodies after being permeabilized by digitonin. Scale bar, 10 mm. (F) Subcellular localization of 11
EGFP-fusion proteins of calu-2 transcripts in HeLa cells, which were co-transfected with GRIP-mRFP and permeabilized by Triton X-100 after fixation.
Numbers indicate the amino acid positions in calu-2. In the cartoon, transcripts which localized on the secretory pathway are marked by green ticks.
Red crosses indicate the transcripts that are smeared in HeLa cells. Scale bar, 10 mm.
doi:10.1371/journal.pone.0035344.g001
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To monitor the intracellular transport and secretory process of
calu-1/2-EGFP, we monitored the distribution and dynamic
behavior of calu-1/2-EGFP in live HeLa cells ($30 cells) using an
Andor spinning disk confocal microscope system. Both calu-1-
EGFP and calu-2-EGFP localized to the secretory pathway,
including the ER network and the Golgi apparatus (Figure 2A).
Calu-1/2-EGFP-containing vesicles were observed throughout the
cytoplasm (Figure 2A). Some appeared to be spherical (Figure 2B),
while others were rod-shaped and tubular (Figure 2C). These calu-
1/2-EGFP-containing vesicles were intracellularly transported
(Figure 2A–C; Movies S1 and S2).
Furthermore, to visualize the details of calu-1/2-EGFP
intracellular transport, we co-expressed calu-1/2-EGFP and
GRIP-mRFP (Golgi marker) in HeLa cells, and viewed the in
vivo motion of calu-1/2-EGFP ($5 cells). These calu-1/2-EGFP-
containing vesicles entered or exited from the Golgi apparatus
(Figure 3A–D). Taken together, calu-1/2-EGFP are distributed in
the secretory pathway and extensively transported within the cell.
Two types of calu-1/2-EGFP secretion
To further visualize the secretory process of calu-1/2-EGFP, we
observed in more detail the in vivo behavior of calu-1/2-EGFP at
the periphery of the cells, and found two main types of secretion.
Some the calu-1/2-EGFP -containing vesicles moved toward the
cell periphery (Figure 4A; Movies S1 and S2). One or two seconds
later, the calu-1/2-EGFP signal faded rapidly and finally vanished,
suggesting that the calu-1/2-EGFP proteins were secreted into the
extracellular space. Interestingly, we noted another secretory
manner, in which vesicles were transported towards the periphery
of the cell and accumulated at cellular processes (Figure 4B;
Movies S1 and S2). We also noted that these cell-tip-heading
vesicles seemed to fuse with each other before being secreted
together (Figure 4C), indicating that calu-1/2-EGFP proteins were
secreted collectively after their accumulation in the tip of cells.
Calu-1/2-EGFP-containing vesicles are transported by
Kif5b and cytoplasmic dynein along microtubules
Having visualized the intracellular transport and secretion of
calu-1/2-EGFP, we then further investigated the molecular
mechanism of calu-1/2 transport. To determine whether the
secretion of calu-1/2-EGFP depends on the cytoskeleton, we
treated the calu-1/2-EGFP-overexpressing cells with different
drugs to interfere with the polymerization of microtubules or actin
filaments. Nocodazole binds to b-tubulin and blocks tubulin self-
assembly, thus interfering with the polymerization of microtubules
[18]. Cytochalasin blocks both assembly and disassembly of
individual actin monomers by binding to the plus ends of
microfilaments, thus inhibiting the normal polymerization and
elongation of actin filaments [19]. After nocodazole treatment, the
protein level of calu-2-EGFP markedly deceased in the cultured
medium, while increased a little in the cell lysate (Figure 5A). On
the contrary, cytochalasin treatment did not alter the secretory
level (Figure 5A). Besides, using immunofluorescence assay, we
found calu-1/2-EGFP green dots localized along microtubules to
cellular processes (Figure 5B and S3). Therefore, the secretion of
calu-1/2-EGFP is microtubule dependent but is not affected by
the integrity of actin filament.
To determine which motor protein mediates the calu-1/2-
EGFP transport, we measured the velocities of calu-1/2-EGFP
containing vesicles. We calculated the velocities of more than 2000
dots ($10 cells), and found that calu-1-EGFP-containing vesicles
moved at an average velocity of 1.1560.55 mm/s (Figure 6A),
similar to the average velocity of the vesicles containing calu-2-
EGFP (1.1260.56 mm/s) (Figure 6B). Although some vesicles
moved rapidly, reaching 3 mm/s, frequency count analysis showed
that most vesicles of both calu-1-EGFP and calu-2-EGFP moved
at 0.7–1 mm/s or 1.1–1.5 mm/s (Figure 6A and 6B). These two
peak values indicate that calu-1/2-EGFP-containing vesicles are
transported by two motors with different motilities.
In eukaryotes, there exist two kinds of microtubule motor
proteins, kinesin and dynein, which widely participate in vesicle
transport [20,21]. The velocity of kinesin heavy chain (Kif5b)
motor and cytoplasmic dynein both varied a lot in previous
reports, but many researches showed that both Kif5b and
cytoplasmic dynein move at ,1 mm/s in vivo [22–27]. Considering
that Kif5b and cytoplasmic dynein moved at different directions,
we measured the inward and outward velocity of calu-1/2-EGFP-
containing vesicles separately. We found that calu-1/2-EGFP-
containing vesicles heading the Golgi apparatus moved at
,0.9 mm/s, while those moving towards the cell periphery moved
at ,1.2 mm/s (Figure 6C). These two velocities fit well with the
two peaks and are similar to the previously reported velocities of
Kif5b and cytoplasmic dynein, suggesting that calu-1/2-EGFP-
Figure 2. Time-lapse imaging of the intracellular transport of
calu-1/2-EGFP. (A) Representative images of HeLa cells overexpress-
ing calu-1/2-EGFP. Calu-1/2-EGFP fusion proteins localize in the Golgi
apparatus and the ER networks, with the nuclei indicated. Vesicles are
indicated by arrowheads. Scale bar, 10 mm. (B–C) Representative images
of the intracellular transport of calu-1/2-EGFP. (B) Movements of single
vesicles (indicated by one arrowhead) were tracked, and movements of
rod-shaped vesicles (indicated by two arrowheads) are shown in (C).
Scale bar, 1 mm.
doi:10.1371/journal.pone.0035344.g002
Intracellular Transport of Calumenin
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35344containing vesicles are transported by Kif5b and cytoplasmic
dynein at different speed.
To further confirm our hypothesis, we performed dominant
negative experiments. Overexpressed p50, one subunit of the
dynactin complex, acts as a dominant-negative inhibitor of dynein-
dynactin, and disrupts cytoplasmic dynein-dependent organelle
movement [28]. Kif5b interacts with its cargoes through kinesin
light chain via the kinesin-light-chain binding domain (KLCBD,
amino acids 760–830), or through cargo binding domain (CBD,
amino acids 831–964). Overexpression of the KLCBD and CBD
of Kif5b cause a dominant negative phenotype of Kif5b, through
their competitive cargo binding effect [29,30]. In the cells
transfected with p50, Kif5b-CBD or Kif5b-KLCBD&CBD, the
protein level of calu-2-EGFP in the cultured medium reduced
significantly (Figure 6D and 6E). Besides, overexpression of Kif5b-
KLCBD did not change the secretion level (Figure 6D), suggesting
that the CBD, but not the KLCBD of Kif5b, is involved in the
recognition of calu-1/2-EGFP-containing vesicles. However, we
could not exclude the possibility that the overexpressed Kif5b-
CBD directly inhibited the activity of endogenous Kif5b through
the binding to its motor domain [31]. Therefore, we knocked
down Kif5b, detected the reduced secretion level of calu-2-EGFP
(Figure 6F), further suggesting that Kif5b participated in
transporting calu-1/2-EGFP. Similarly, the knockdown of cyto-
plasmic dynein also reduced the secretion level of clau-2-EGFP
(Figure 6F). Collectively, these data suggested that cytoplasmic
dynein and Kif5b were involved in the transport of calu-1/2-
EGFP-containing vesicles.
To further demonstrate the motor-cargo association, we
performed pull-down and immunoprecipitation analysis. Calu-2-
EGFP was pulled down by GST-Kif5b-CBD (Figure 6G).
Immunoprecipitation assay also confirmed the association between
Figure 3. Calu-1/2-EGFP enter or exit the Golgi apparatus. (A–D) The representative HeLa cells transfected with calu-1-EGFP (A and B) and
calu-2-EGFP (C and D) visualized by the Andor spinning disk confocal microscope system. The rectangles show magnified areas. Arrowheads point to
those vesicles which enter (A and C) and exit (B and D) the Golgi apparatus. The time interval between two individual frames is 0.48 seconds. Scale
bar, 1 mm.
doi:10.1371/journal.pone.0035344.g003
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Meanwhile, overexpressed Kif5b-CBD dramatically decreased
the number of moving calu-1/2-EGFP vesicles (Figure 7; Movies
S3, S4, S5, S6). Taken together, calu-1/2-EGFP-containing
vesicles are transported by Kif5b and cytoplasmic dynein, and
the Kif5b-CBD and dynactin are necessary for calu-1/2-EGFP
secretion.
Export signal of calu-1/2-EGFP
Soluble cargo proteins in the intracellular lumen are exported
by either bulk flow or receptor-mediated transport [32–37]. To
investigate whether calu-1/2-EGFP is passively or actively
exported into the extracellular space, we expressed the fusion
proteins SP19-EGFP, which are the EGFP-tagged N-terminal 19
amino acids of calu-1/2 (Figure 8A). If the secretion of calu-1/2-
EGFP is through bulk flow, SP19-EGFP should have the same
percentage secretion as full-length calu-1/2-EGFP. However, we
found that the percentage secretion of SP19-EGFP was dramat-
ically decreased compared to the calu-2-EGFP (Figure 8A). To
exclude the possibility that N-terminal signal peptide cleavage of
SP19-EGFP was disrupted, thus leading to its retention, we further
studied SP22-EGFP. SP22-EGFP showed similar percentage
secretion to SP19-EGFP (Figure 8A), suggesting that calu-1/2
may not be secreted through bulk flow but via receptor-mediated
secretory pathway.
Next, to identify the export signal for the calu-1/2 secretion, we
constructed transcripts of calu-2(D1–D6)-EGFP (Figure 8A). The
percentage secretions of calu-2(D1–D3)-EGFP were nearly the
same as that of calu-2-EGFP; on the contrary, calu-2(D4–D6)-
EGFP exhibited a significant reduction of secretory level
Figure 4. Calu-1/2-EGFP are secreted in two different types. (A) Time-lapse observation of calu-1-EGFP (left) and calu-2-EGFP (right) secretion
in the ‘‘secretion after attachment’’ mode. Scale bar, 4 mm. (B) Vesicle tracks in calu-1-EGFP-expressing HeLa cells. Images were acquired at 0.188-
second intervals. These sequential frames were overlaid as time projections to illustrate vesicle paths. The rectangles are magnified areas showing the
accumulation of calu-1-EGFP in the cellular processes. Scale bar, 10 mm. (C) Time-lapse observation of calu-1-EGFP secretion in the ‘‘secretion after
accumulation’’ mode. Note that the arrow head pointed calu-1-EGFP dots moved to the arrow pointed dot, and the arrow pointed dot vanished
finally. Scale bar, 4 mm.
doi:10.1371/journal.pone.0035344.g004
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crucial for the receptor-mediated export of calu-1/2-EGFP, was
located between the amino acid positions 20 and 46. Furthermore,
within the sorting signal, we noted that the proline at site 21 was
reported to be an ER export signal [14]. To determine whether
this site alone plays a vital role in calu-1/2-EGFP secretion, we
mutated it to alanine, and measured the percentage secretion. The
percentage secretion of calu-2-P21A-EGFP was only slightly
decreased compared with the control (Figure 8B and 8C),
suggesting that the proline at site 21 is not the only key element
for calu-1/2-EGFP secretion but may contribute to the integrity of
the sorting signal between amino acids 20–46.
Asparagine at site 131 is important for calu-1/2-EGFP
stability
The asparagine at site 131 is predicted to be an N-glycosylation
site [8,11]. To test this hypothesis, we investigated whether this site
affects calu-1/2-EGFP secretion. Surprisingly, we found that when
the asparagine at position 131 was mutated to alanine, calu-
2(N131A)-EGFP was degraded extensively both in the intracellular
and extracellular space (Figure 8B), suggesting that the N-
glycosylation at this site plays an important role in calu-1/2-
EGFP stability, which needs further investigation.
Discussion
In this study, we showed that calu-1/2-EGFP are translocated
into the lumen with the help of their signal peptide, transported
intracellularly in vesicles, and finally secreted into the extracellular
space (Figure 9), during which the sorting signal on calu-1/2 is
indispensable. We examined the velocities of calu-1/2-EGFP-
containing vesicles, and identified the motor proteins that
participate in powering calu-1/2-EGFP-containing vesicles. Most
interestingly, besides the traditional mode of secretion, we also
observed another type of secretion, in which calu-1/2-EGFP-
containing vesicles accumulated in cellular processes and were
secreted collectively.
During the secretory process, protein with an N-terminal signal
peptide is synthesized in the rough ER-bound ribosomes and then
translocated into the ER lumen. After proper folding and
modification, the protein is delivered to the Golgi apparatus for
further modification and finally released into the extracellular
space through vesicular transport [38]. Among the various motor
proteins responsible for the intracellular transport of diverse
cargoes, the microtubule motor protein cytoplasmic dynein moves
towards the minus end of the microtubules, participating in
anterograde transport from the ER to the Golgi apparatus [21,39],
and Kif5b, a microtubule plus end-directed motor, is responsible
for post-Golgi traffic [20,40]. Previous reports about the velocities
Figure 5. The transport of calu-1/2-EGFP-containing vesicles are microtubule-dependent but actin-independent. (A) Western blotting
analysis in TCL and CM of the calu-2-EGFP transfected cells treated with DMSO, nocodazole or cytochalasin. (B) Immunofluorescence of calu-2-EGFP
expressing HeLa cells using anti-a-tubulin antibody. Arrow heads indicate calu-2-EGFP dots spreading along the microtubules to cellular processes.
The rectangle areas were amplified. Scale bar, 10 mm.
doi:10.1371/journal.pone.0035344.g005
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to larger than 3 mm/s [22–27,41–44]. In our experiments, calu-1/
2-EGFP-containing vesicles also moved at different speeds, with
some moved at 0.3–0.5 mm/s while some fast vesicles reached
3 mm/s. This is consistent with previous reports. Besides, we found
that calu-1/2-EGFP-containing vesicles moved at ,0.9 mm/s
inward and ,1.2 mm/s outward. We hypothesized that cytoplas-
mic dynein and Kif5b were responsible for the intracellular
transport of calu-1/2-EGFP at different speeds. Using dominant
negative and RNAi methods, we found that the blockage of Kif5b
or cytoplasmic dynein significantly inhibited the secretion of calu-
1/2-EGFP (Figure 6D–F). Moreover, GST pull-down and
Figure 6. Calu-1/2-EGFP-containing vesicles are transported by Kif5b and cytoplasmic dynein. (A–B) Histograms show the distribution of
velocities of calu-1/2-EGFP-containing vesicles in HeLa cells. The dashed lines indicate that most vesicles move at 0.7–1 mm/s and 1.1–1.5 mm/s.
Approximately 2000 dots ($10 cells) were measured for each group. (C) The inward and outward velocity of calu-1/2-EGFP-containing vesicles. (D)
Western blotting analysis of calu-2-EGFP secretory level in HeLa cells co-transfected with the indicated dominant negative vectors. (E) Western
blotting analysis of calu-2-EGFP secretory level in HEK293T cells co-transfected with the indicated dominant negative vectors. (F) Western blotting
analysis of calu-2-EGFP secretory level of Kif5b or cytoplasmic dynein knockdown HeLa cells. (G) GST pull-down analysis of calu-2-EGFP transfected
cells using GST or GST-Kif5b-CBD. (H) Immunoprecipitation assay of calu-2-EGFP and myc-p150 overexpressing HEK293T cells using normal IgG or
anti-myc antibody.
doi:10.1371/journal.pone.0035344.g006
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between Kif5b/cytoplasmic dynein and calu-1/2-EGFP-contain-
ing vesicles (Figure 6G–H). Therefore, it is possible that
cytoplasmic dynein mediates the ER-to-Golgi transport of calu-
1/2-EGFP at a relatively slower speed of ,0.9 mm/s, while Kif5b
executes the transport of calu-1/2-EGFP-containing vesicles at
,1.2 mm/s during post-Golgi transport (Figure 9). Also, we do not
exclude the possibility that calu-1/2-EGFP-containing vesicles are
bidirectionally transported through spatial-temporal regulation of
Kif5b and dynein cooperation [45,46], and some other motor
proteins may also be involved in the transport of calu-2-EGFP.
In our experiments, we found two types of secretion of calu-1/2-
EGFP. In the model of ‘‘secretion after attachment’’ (Figure 9B),
which is traditionally reported [42], the release of the secretory
product is thought to be regulated by the network of actin
filaments. It was suggested that the secretory vesicles traveling to
the periphery of the cell are inhibited to fuse with each other and
the plasma membrane by a dense web of microfilaments, and the
stimulation of the rapid depolymerization of these actin filaments
leads to the following vesicle fusion and secretion [47,48].
However, our results show that the disruption of actin filament
network does not enhance the secretory level of calu-2-EGFP
(Figure 5A), suggesting most calu-1/2-EGFP may not use this
secretory mode, but are secreted through the model of ‘‘secretion
after accumulation’’ (Figure 9C), which is also observed in mRNA
trafficking [49]. Moreover, the projection of the green fluorescent
dots (Figure 4B) not only stands for the trafficking paths of calu-1/
2-EGFP-containing vesicles, but may also represent the microtu-
bule tracks. This is further supported by the immunostaining data,
in which microtubules pointed to cellular processes with calu-2-
EGFP dots aligning along them (Figure 5B and S3). Therefore, we
propose that it is the microtubules directed towards cellular
processes that facilitate the accumulation of calu-1/2-EGFP-
containing vesicles. Previous reports show that exocytotic vesicles
are targeted to the ELKS-containing patches where MT plus ends
are attached [42,50]. So it is possible that the cellular processes are
abundant with ELKS and attract calu-1/2-EGFP-containing
vesicles.
Soluble proteins with ER exit signals are recognized by
transmembrane receptors, which recruit the coat proteins, and
mediate the transport from the ER to the Golgi apparatus, and
finally to the cell periphery [32,33,35]. Besides, some proteins
without ER exit signals also enter secretory vesicles and are
secreted [34,37]. Our data indicate that calu-1/2-EGFP are
secreted through the receptor-mediated pathway, with their exit
signal located at amino acid positions 20–46.
In addition, we identified the asparagine at position 131, which
was predicted to be a glycosylation site [8,11], as essential for calu-
1/2-EGFP stability. The asparagine to alanine mutation lead to
Figure 7. Dominant negative effects of Kif5b on the calu-1/2-
EGFP-containing vesicle trafficking in HeLa cells. (A) The
representative picture shows the tracks of moving vesicles containing
calu-1-EGFP in the presence of mRFP or mRFP-Kif5b-CBD. These tracks
of moving vesicles are real-time projections of individual frames over
3 minutes. (B) The numbers of moving calu-1-EGFP-containing vesicles
per minute corresponding to (A) were manually counted ($10 cells in
each group). (C) The representative picture shows the tracks of moving
vesicles containing calu-2-EGFP in the presence of mRFP or mRFP-Kif5b-
CBD. These tracks of moving vesicles are real-time projections of
individual frames over 3 minutes. (D) The numbers of moving calu-2-
EGFP-containing vesicles per minute corresponding to (C) were
manually counted ($10 cells in each group). Scale bar, 10 mm.
doi:10.1371/journal.pone.0035344.g007
Figure 8. The export signal for calu-1/2-EGFP. (A) Percentage
secretion of different calu-2 truncated constructs. The right column
shows the percentage secretion of nine constructs showed in the left
column. These secretory rates were calculated according to the Western
blotting results (data not shown, three independent experiments). (B)
Point mutation effects on calu-2-EGFP secretion. Western blotting
analysis showed calu-2-EGFP secretory level of two point mutations.
Samples were probed with anti-EGFP and anti-tubulin antibodies. Co.St.
was used as a loading control of CM. (C) The percentage secretion of
calu-2-EGFP mutation constructs shown in (B) (three independent
experiments).
doi:10.1371/journal.pone.0035344.g008
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extracellularly. This can be explained by two possibilities: either
the glycosylation at this site stabilize calu-2-EGFP, protecting it
from being cleaved by protease, or the mutation itself leads to
misfolding of calu-2(N131A)-EGFP, its stuck in the ER and
subsequent degradation via the ERAD pathway. Further exper-
iments are needed to uncover the detailed mechanism.
Materials and Methods
Cell culture and transfection
HeLa [30] and HEK293T cells [51] were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO BRL)
supplemented with 10% FBS at 37uC with 5% CO2 as described
previously [30,52]. Calcium phosphate precipitation or jetPEI
(Polyplus) was used to transiently transfect HeLa and HEK293T
cells according to previous reports [53].
Antibodies
Mouse anti-human calu-2 polyclonal antibody (pAb) and rabbit
anti-EGFP pAb were developed using prokaryotic expressed and
purified protein GST-calu-2. Mouse anti-human calu-2 pAb
recognizes both the calu-1 and -2 isoforms (data not shown). Anti-
Kif5b antibody was produced previously [54]. Anti-PDI (ab2792),
anti-GAPDH (ab8245), anti-GM130 (ab1299) and anti-Giantin
(ab24586) were from Abcam. Anti-a-tubulin (DM1a) was from
Sigma. Anti-myc antibody (M047-3) was from MBL. The
secondary antibodies Alexa Fluor 488-/568-conjugated goat
anti-mouse/rabbit IgG antibodies (Invitrogen) and HRP-conju-
gated antibodies (Invitrogen) were used in immunofluorescence
and Western blotting analysis following the manufacturers’
instructions.
Vector construction
Calu-1/2 transcripts were amplified from HeLa cDNA and
inserted into the EcoRI/SalI site on the pEGFP-N3 vector
(Clontech). Two point mutations of calu-2, P21A and N131A,
were also constructed into the pEGFP-N3 vector (see supplemen-
tary material Table S1 for primer information). APP-EGFP vector
was obtained by cloning APP into the XhoI/SalI site on the pEGFP-
N3 vector. The b4GalT-1-EYFP encodes an EYFP-tagged fusion
protein containing the N-terminal 81 amino acids of human
b4GalT-1. GRIP-mRFP encodes a fusion protein to mark the Golgi
apparatus as previously reported [55]. Vector p50-EGFP was from
Figure 9. Schematic diagram illustrating the intracellular transport and secretory process of calu-1/2-EGFP. (A) In the eukaryotic cell,
calu-1/2-EGFP are simultaneously synthesized and translocated into the lumen of the endoplasmic reticulum, and then exit the ER with the help of
the motor protein cytoplasmic dynein, being enclosed in vesicles (step I). After entering the Golgi apparatus, calu-1/2-EGFP are glycosylated and then
transported within the secretory vesicles along microtubules by Kif5b to the periphery of the cell (step II). Then, calu-1/2-EGFP are secreted to the
extracellular space either directly after attaching to the cell membrane (step III) or first accumulate in cellular processes and then are released
together (step IV). (B) Model for ‘‘secretion after attachment’’. (C) Model for ‘‘secretion after accumulation’’.
doi:10.1371/journal.pone.0035344.g009
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and inserted into the EcoRI/SalI site on pmRFP-C1 (Clontech).
Kif5b-CBD (amino acids 831–964), Kif5b-KLCBD (amino acids
760–830),and Kif5b-KLCBD&CBD wereamplified from cDNA of
HeLa cells, and inserted into the EcoRI/SalI site on pmRFP-C1
(Clontech). Myc-p150 [56] was constructed into the BamHI/XhoI
site of pcDNA3.1 vector. See Table S1 for primer information.
Immunoblotting analysis and percentage secretion
ProteinswereseparatedbySDS-PAGEandthentransferredonto
PVDF membranes (Millipore) in a semidry transfer cell (Bio-Rad).
The membranes were blocked and subsequently probed with
primary and secondary antibodies as previously reported [57].
For detecting the protein level in the cultured medium of HeLa
cells, we substituted the medium with the serum-free DMEM
24 hours after transfection, and collected the total cell lysate (TCL)
and the corresponding serum-free cultured medium (CM) from
eachcell culture dish48 hours after transfection.As for experiments
in HEK293T cells, we changed the medium with serum-free
medium 12 hours post transfection and collected for 24 hours. Both
TCL and CM were compressed to 50 mL, and a fifth of the total
sample (10 mL) was loaded and subjected to Western blotting. The
intensity of each target band was quantified using Image J analysis
software (NIH). The percentage secretion is the ratio of the band
intensity in the CM to the total intensity of the target band in both
TCL and CM. Besides, in some experiments, cells were treated with
DMSO, nocodazole (2 mg/ml), and cytochalasin B (1 mg/ml) in
serum-free medium, and the TCL and CM were collected 24 hours
later for Western blotting analysis.
Fluorescence microscopy and time-lapse imaging
Transfected HeLa cells were fixed with freshly prepared 4%
paraformaldehyde in PBS, and then subjected to direct observa-
tion under a fluorescence microscope (Olympus) or a confocal
microscope (Leica). For immunofluorescence, the fixed cells were
incubated with antibodies after permeabilization (0.15% Triton X-
100 in PBS) and blocking. For digitonin treatment, the cells were
permeabilized with 25 mg/ml digitonin in KHM buffer on ice as
previously reported [17], and then fixed with 4% paraformalde-
hyde. For live cell imaging, the transfected cells were subjected to
spinning disk laser microscopy (Andor) 24 hours after transfection.
Images were collected using Andor software.
RNA interference
ForknockdownexperimentinHeLacells,siRNAstargetingKif5b
and cytoplasmic dynein according to previously report [42] were
synthesized, and transfected into the HeLa cells using Lipofectamine
2000 (Invitrogen) as the manufacture’s instruction. Control scramble
sequence were designed by GenePharma Co.,Ltd.
Pull-down and immunoprecipitation
For pull-down analysis, the fusion protein GST-Kif5b-CBD was
prokaryotically expressed and attached to glutathione-sepharose
4B beads (Amersham). The total cell lysate of calu-2-EGFP
transfected HEK293T cell was then collected and incubated with
the affinity column in lysis buffer (20 mM HEPES, 120 mM NaCl,
5 mM EGTA, 2 mM MgCl2 and 1 mM DTT, pH 7.4) at 4uC
overnight. The combined protein was harvested and tested by
Western blotting.
For immunoprecipitation assay, the calu-2-EGFP and myc-
p150 transfected HEK293T cell was lysed in IP buffer (20 mM
HEPES, 250 mM sucrose, 10 mM KCl, 1 mM EGTA, 1 mM
EDTA, 1.5 mM MgCl2 and 1 mM DTT, pH 7.4) containing
protease inhibitor cocktail (Roche). Then, nucleus were removed
by centrifugation at 3,000 rpm for 5 minutes. The supernatant
was further centrifugated at 8,000 rpm for 15 minutes to remove
mitochondria. The remained cytosolic and membrane fraction
was then incubated with anti-myc antibody at 4uC overnight. The
protein samples that combined with the Protein A Sepharose
(Amersham) were collected and subjected to Western blotting.
Statistical analysis
Images analyzed using Andor software and Image J (NIH).
Vesicle motility (with a velocity exceeding 0.3 mm/s), relative
fluorescence intensity, and vesicle path projection were acquired as
previously reported [24,42]. The velocities of moving vesicles were
measured using the Image J software (NIH). The distance that one
dot moved every two frames was calculated, with dots tracked
manually, and the corresponding velocity was measured according
to the interval time (0.376 seconds). Approximately 2000 dots ($10
cells) were measured for each group. As for the calculation of the
number of moving vesicles, we manually counted the number of
moving dots in each cells for one minute ($10 cells in each group).
Results arepresentedasmean6standarddeviation.Comparisons
were analyzed by unpaired, two-sided, independent student’s t test
with or without equal variance assumption, according to the result of
an F test. * means p,0.05, ** means p,0.01, *** means p,0.001.
Supporting Information
Figure S1 Immunofluorescence of HeLa and HEK293T cells
probed with anti-calu-1/2 antibody or anti-Giantin antibody.
Scale bar, 10 mm.
(TIF)
Figure S2 Immunofluorescence of HeLa cells probed with anti-
GM130 antibody or anti-PDI antibody after digitonin or Triton
X-100 treatment. Scale bar, 10 mm.
(TIF)
Figure S3 Immunofluorescence of EGFP or Calu-2-EGFP
overexpressing HEK293T cells probed with anti-a-tubulin
antibody. The rectangle areas were magnified. Scale bar, 10 mm.
(TIF)
Table S1 Sequence information of primers used.
(DOC)
Movie S1 Intracellular transport of calu-1-EGFP-con-
taining vesicles. The video records the movement of calu-1-
EGFP-containing vesicles in HeLa cells at 0.188-seceond interval
for 38 seconds. The time and scale are indicated.
(AVI)
Movie S2 Intracellular transport of calu-2-EGFP-con-
taining vesicles. The video records the movement of calu-2-
EGFP-containing vesicles in HeLa cells for 38 seconds. The time
and scale are indicated.
(AVI)
Movie S3 Transport of calu-1-EGFP in HeLa cells
overexpressing mRFP. The video records the movement of
calu-1-EGFP-containing vesicles in HeLa cells at 0.188-seceond
interval for 38 seconds. The scale is indicated.
(AVI)
Movie S4 Transport of calu-1-EGFP in HeLa cells
overexpressing mRFP-Kif5b-CBD. The video records the
movement of calu-1-EGFP-containing vesicles in HeLa cells at
0.188-seceond interval for 38 seconds. The scale is indicated.
(AVI)
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overexpressing mRFP. The video records the movement of
calu-2-EGFP-containing vesicles in HeLa cells at 0.188-seceond
interval for 38 seconds. The scale is indicated.
(AVI)
Movie S6 Transport of calu-2-EGFP in HeLa cells
overexpressing mRFP-Kif5b-CBD. The video records the
movement of calu-2-EGFP-containing vesicles in HeLa cells at
0.188-seceond interval for 38 seconds. The scale is indicated.
(AVI)
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